Avadel Pharmaceuticals (Avadel Pharmaceuticals) EV-to-Revenue : 54.03 (As of Apr. 27, 2024)

View and export this data going back to 1996. Start your Free Trial

What is Avadel Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Avadel Pharmaceuticals's enterprise value is $1,510.74 Mil. Avadel Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $27.96 Mil. Therefore, Avadel Pharmaceuticals's EV-to-Revenue for today is 54.03.

The historical rank and industry rank for Avadel Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

AVDL' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.54 Med: 11.73 Max: 758.48
Current: 54.03

During the past 13 years, the highest EV-to-Revenue of Avadel Pharmaceuticals was 758.48. The lowest was 0.54. And the median was 11.73.

AVDL's EV-to-Revenue is ranked worse than
95.81% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs AVDL: 54.03

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-27), Avadel Pharmaceuticals's stock price is $17.81. Avadel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.31. Therefore, Avadel Pharmaceuticals's PS Ratio for today is 56.90.

Avadel Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Avadel Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals EV-to-Revenue Chart

Avadel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

5.81

13.40

41.69

Avadel Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															-	-	891.49	93.03	41.69

Competitive Comparison of Avadel Pharmaceuticals's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avadel Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Avadel Pharmaceuticals's EV-to-Revenue falls into.

Avadel Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Avadel Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	1510.741	/	27.963
	=	54.03

Avadel Pharmaceuticals's current Enterprise Value is $1,510.74 Mil.
Avadel Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.96 Mil.

Avadel Pharmaceuticals (NAS:AVDL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Avadel Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	17.81	/	0.313
	=	56.90

Avadel Pharmaceuticals's share price for today is $17.81.
Avadel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.31.

Avadel Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Avadel Pharmaceuticals (Avadel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (NAS:AVDL) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

AWK1:Germany AWK1:Germany

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.avadel.com

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.

Executives

Thomas S Mchugh	officer: Chief Financial Officer	2280 SCHUETZ ROAD, ST. LOUIS MO 63146
Mark Anthony Mccamish	director	C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Geoffrey Michael Glass	director	4721 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Greg J Divis	director, officer: Chief Executive Officer	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Richard J Kim	officer: Chief Commercial Officer	16 FAIRWAY DRIVE, WEST WINDSOR NJ 08550
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Linda Palczuk	director	7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD 21046
Peter Thornton	director	TECHNOPATH LIFE SCIENCES PARK, FORT HENRY, BALLINA, CO. TIPPERARY L2 V94 FF1P
Douglas J Williamson	officer: Chief Medical Officer	AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Sandra L Hatten	officer: See Remarks	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jason Vaughn	officer: Sr. VP, Technical Operations	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jordan Dubow	officer: Chief Medical Officer	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Michael F Kanan	officer: See Remarks	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
David P Gusky	officer: See Remarks	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Michael S Anderson	director, officer: Chief Executive Officer	10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15